Nektar Therapeutics (NKTR) Balance Sheet

Click line-items for a historical chart and %

Cash and cash equivalents	63.3M
Short-term investments	190.22M
Accounts receivable	14.25M
Inventory	10.75M
Other current assets	4.01M
Total current assets	282.52M
Long-term investments
Property and equipment, net	65.55M
Goodwill	76.5M
Other assets	519K
Total assets	425.1M
Accounts payable	7.12M
Accrued compensation	15.73M
Accrued expenses
Accrued clinical trial expenses	10.95M
Deferred revenue, current portion	14.1M
Other current liabilities	2.58M
Total current liabilities	76.31M
Convertible subordinated notes
Capital lease obligations, less current portion	2.14M
Deferred revenue, less current portion	57.09M
Deferred gain
Other long-term liabilities	5.52M
Total liabilities	492.95M
Commitments and contingencies
Preferred stock, 10,000 shares authorized Series A, $0.0001 par value; 3,100 shares designated; no shares issued or outstanding at June 30, 2011 and December 31, 2010	0
Common stock, $0.0001 par value; 300,000 authorized; 114,305 shares and 94,517 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively	13K
Capital in excess of par value	1.91B
Accumulated other comprehensive income	-1.96M
Accumulated deficit	-1.98B
Total stockholders' equity	-67.85M
Total liabilities and stockholders' equity	425.1M

Entities mentioned with NKTR

View All Entities